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Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare but serious disease with poorly
understood mechanisms. Here, we report that patients with EGPA have elevated levels of TSLP,
IL-25, and soluble ST2, which are well-characterized cytokine “alarmins” that activate or modulate
type 2 innate lymphoid cells (ILC2s). Patients with active EGPA have a concurrent reduction
in circulating ILC2s, suggesting a role for ILC2s in the pathogenesis of this disease. To explore
the mechanism of these findings in patients, we established a model of EGPA in which active
vasculitis and pulmonary hemorrhage were induced by IL-33 administration in predisposed,
hypereosinophilic mice. In this model, induction of pulmonary hemorrhage and vasculitis was
dependent on ILC2s and signaling through IL4Rα. In the absence of IL4Rα or STAT6, IL-33–treated
mice had less vascular leak and pulmonary edema, less endothelial activation, and reduced
eotaxin production, cumulatively leading to a reduction of pathologic eosinophil migration into
the lung parenchyma. These results offer a mouse model for use in future mechanistic studies of
EGPA, and they suggest that IL-33, ILC2s, and IL4Rα signaling may be potential targets for further
study and therapeutic targeting in patients with EGPA.
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Eosinophilic granulomatosis with polyangiitis (EGPA), is a rare but potentially life-threatening disease
with few effective treatments (1–3). The initial phase, characterized by asthma and other allergic symptoms, is followed by tissue and blood hypereosinophilia, and later by systemic necrotizing vasculitis (1–3).
Eosinophils, which typically represent approximately 1% of peripheral blood leukocytes (4), reach 10%
or greater in EGPA (3). Eosinophils accumulate in the extravascular space, sometimes in pathognomonic
granulomas. Their aggregation and activation around small vessels result in ischemic or thrombotic tissue
damage (“vasculitis”) (3). Accordingly, treatment with anti–IL-5 mAb yields clinical improvement in some
patients (2). Hypereosinophilia alone — which also occurs in medication reactions, hematologic malignancy, allergy, or parasite infection — is not sufficient to cause vasculitis (5–8). But it remains unclear what
additional signals induce disease, or what tissue specific signals explain predilection for particular organs
such as airways, peripheral nerves, skin, and heart (3).
Given the similarities with allergic asthma, the presumption has been that eosinophil activity is driven
by Th type 2 (Th2) cells. However, this hypothesis remains unproven, in part because rodent models that
recapitulate human disease are lacking (3). In addition, a role for type 2 innate lymphoid cells (ILC2s),
tissue-resident innate counterparts to Th2 cells that are highly responsive to IL-25, TSLP, and IL-33 (9), has
not been explored. ILC2s constitutively produce IL-5, which is important for controlling tissue accumulation of eosinophils (10) as well as other type 2 cytokines such as IL-4 and IL-13. In this study, we examine
a role for tissue cytokines in activation of ILC2s in patients with EGPA and establish a mouse model to
study this complex and devastating disease.
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Results
Patients with EGPA had elevated type 2 cytokines in serum and altered ILC2 numbers. We quantified increased
serum levels of IL-5 and IL-10 among patients with EGPA (Supplemental Figure 1, A and B; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.143366DS1), particularly
during active disease. We reasoned that alarmins known to potentiate IL-5 production might act upstream
of these effector cytokines in patients with EGPA. GWAS analysis identifies variants in the gene encoding
TSLP in patients with EGPA (11), and both IL-25 (12) and IL-33 (13) have previously been reported to be
elevated in patients with active EGPA. Indeed, we observed that patients with EGPA had elevated serum
levels of IL-25, TSLP, and soluble ST2 (sST2), the decoy receptor for IL-33 (Figure 1, A–C), whereas IL-33
was not detected in serum from patients with EGPA or controls (data not shown).
Because these cytokines can activate ILC2s, a major source of IL-5, we hypothesized that ILC2s
might contribute to disease in patients with EGPA. Peripheral blood ILC2s were significantly decreased
in patients with EGPA (Figure 1D and Supplemental Figure 1C). Because ILC2s are predominantly tissue
resident (14), we hypothesize that elevated tissue cytokines may induce migration and retention of circulating ILC2s into diseased tissues in EGPA, as previously described in allergic asthma (15).
IL-33 treatment in hypereosinophilic mice caused eosinophilic vasculitis. To test the role of ILC2s and their
activating cytokines in pathogenesis of eosinophilic vasculitis, we employed a previously described mouse
model wherein IL-5 is expressed as a transgene from the CD3δ promoter (herein designated as “IL5Tg”),
resulting in approximately 100-fold normal levels of circulating eosinophils (>60% of total peripheral
blood leukocytes, progressive with age) (5). These mice have diffuse organ infiltration with eosinophils,
splenomegaly, and lymphocytosis but do not exhibit spontaneous eosinophilic vasculitis.
Treatment of IL5Tg mice intranasally with IL-33 but not IL-25, TSLP, or saline over a 2-week period led to alveolar hemorrhage (Figure 2, A and B, and Supplemental Figure 3A). Saline-treated IL5Tg
mice showed pulmonary eosinophilia with peribronchovascular eosinophilic clusters (Figure 2C), as previously described (5, 8). IL-33–treated WT mice showed lymphocytic infiltration and perivascular lymphoid aggregates, consistent with lymphocytic pneumonia (Figure 2C). In contrast, lungs of IL-33–treated
IL5Tg mice showed dense patches of perivascular and peribronchial inflammatory infiltrates, individual
and clustered multinucleated giant cells, nodular areas of necrosis, intra-alveolar fibrin deposits, eosinophilic vasculitis, and alveolar hemorrhage (Figure 2C and Supplemental Figure 3, B–G). Treatment of
IL5Tg mice with IL-33, but not IL-25 or TSLP, also induced a synergistic increase in bronchoalveolar
lavage (BAL) eosinophilia (Figure 2D and Supplemental Figure 2). IL-33 dramatically increased ILC2s
in the BAL in both WT and IL5Tg mice (Figure 2E), as previously described (16). The number of eosinophils and ILC2s in lung tissue and BAL were closely correlated, indicating the utility of BAL in assessing
the tissue inflammatory state (Supplemental Figure 3, H and I).
EGPA can manifest in numerous tissues, including skin. Although we observed collections of eosinophils in skin of saline-treated IL5Tg mice, the cutaneous vessels appeared normal (Supplemental Figure 3J). However, when IL5Tg mice were treated with IL-33, we observed eosinophilic infiltration of the
perivascular space and vascular walls (Supplemental Figure 3J). Antineutrophil cytoplasm Abs (ANCAs),
which are found in about a third of patients with EGPA (17), were not increased in IL5Tg mice, with or
without cytokine treatment (data not shown). Thus, IL-33 treatment of IL5Tg mice recapitulated aspects
of eosinophilic vasculitis in patients with EGPA.
ILC2s were required for the development of vasculitis in hypereosinophilic mice. To test the role of ILC2s in
vasculitis, we crossed IL5Tg mice to Il5Red5CreROSA-DTA ILC2-deficient R5/R5 deleter (ILC2del) mice, in
which mature ILC2s — which constitutively produce IL-5 — are deleted via Cre-inducible expression of
diphtheria toxin alpha from the endogenous IL-5 promoter (10). ILC2del x IL5Tg mice were protected from
pulmonary hemorrhage after IL-33 (Figure 3A) and had dramatically blunted BAL eosinophilia (Figure
3B) despite insignificant changes in peripheral eosinophilia (Supplemental Figure 4B). As expected, ILC2s
were absent from the BAL in ILC2del mice (Figure 3C). ILC2del mice were rescued from histopathologic
findings of eosinophilic vasculitis (Figure 3D). Even during IL-33 administration, ILC2s were the predominant population of IL-5–expressing cells in the mouse lung (Supplemental Figure 4A), indicating that
deletion of Th2 cells was unlikely to explain the absence of vasculitis.
IL4Rα signaling was required for the development of vasculitis in hypereosinophilic mice. ILC2s produce numerous effector molecules, including IL-5, IL-13, IL-9, and amphiregulin (9). We reasoned that in the context
of systemic IL-5 overexpression, the contribution of ILC2-derived IL-5 was likely negligible. After IL-33
JCI Insight 2021;6(11):e143366 https://doi.org/10.1172/jci.insight.143366
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Figure 1. Patients with EGPA have elevated type 2-activating cytokines and altered ILC2 numbers in blood. (A) IL-25, (B)
sST2, and (C) TSLP from HCs or patients with EGPA with iEGPA or aEGPA. n = 20–53 per group. (D) Peripheral blood ILC2s
measured from HCs or patients with EGPA with iEGPA or aEGPA. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05 by
Brown-Forsythe and Welch ANOVA with Dunnett’s post hoc testing. n = 6–18 patients per group. EGPA, eosinophilic granulomatosis with polyangiitis; ILC2s, type 2 innate lymphoid cells; sST2, soluble ST2; HCs, healthy controls; iEGPA, inactive
disease; aEGPA, active disease.

administration, ILC2s were the major IL-13–producing cell type in the lung (Figure 3E), suggesting that
ILC2-derived IL-13 might have been implicated in the pathogenesis of eosinophilic vasculitis in our model.
To investigate the role of IL4Rα signaling in our model, we generated IL5Tg mice with cells
unresponsive to IL-4 and IL-13 signaling by crossing to IL4Rα–/– (the receptor for IL-4 and IL-13) or
STAT6–/– (required for downstream signaling). Like ILC2del mice, IL4Rα–/– x IL5Tg and STAT6-–/– x
IL5Tg mice were protected from pulmonary hemorrhage after IL-33 administration (Figure 4A) and
had dramatically reduced BAL eosinophilia compared with controls (Figure 4B). The number of ILC2s
in the BAL, however, was unaffected in STAT6–/– mice and minimally affected by the loss of IL4Rα
(Figure 4C). Thus, IL-4 and IL-13 signaling is dispensable for ILC2 expansion and appearance in the
BAL and may rather be necessary for their pathologic effect. Consistent with the loss of hemorrhage
and eosinophils from BAL, IL5Tg mice on either IL4Rα–/– or STAT6–/– backgrounds were rescued from
histopathologic evidence of eosinophilic vasculitis (Figure 4, D–H). The degree of rescue was more
profound with STAT6–/– or IL4Rα–/– than with ILC2del (Figure 4, E–H), suggesting either incomplete
deletion of ILC2s or production of IL-13 or IL-4 by other cells. Importantly, STAT6–/– x IL5Tg or
IL4Rα–/– x IL5Tg mice had comparable blood eosinophilia, and ILC2 expansion after IL-33 treatment
was equivalent (Supplemental Figure 5, A and B).
IL-33 caused IL4Rα-dependent acute lung injury and pulmonary vascular leak. We suspected that IL-33-induced IL4Rα/STAT6-dependent signal(s) give eosinophils access to tissue-derived factors, resulting in
degranulation and pathology. Indeed, IL-33 treatment caused severe pulmonary edema, as measured by
excess/extravascular lung water (ELW), and increased vascular permeability, as measured by extravascular
JCI Insight 2021;6(11):e143366 https://doi.org/10.1172/jci.insight.143366
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Figure 2. IL-33 and hypereosinophilia synergize to cause eosinophilic vasculitis in mice. (A) Representative bronchoalveolar lavage and (B) representative
whole lungs from IL-33–treated WT or IL5Tg mice. Images in A and B are representative of 3 or more mice/group, in a minimum of 3 independent experiments. (C) H&E staining of lungs from representative IL-33–treated WT or IL5Tg mice, as shown in A and B (original magnification, ×20). Scale bars: 100
μm. (D) Eosinophils or (E) ILC2s in BAL. Data are presented as ± SEM. ****P < 0.0001; ***P < 0.001 by 1-way ANOVA with Sidak post hoc testing. n = 3–4
mice/group. BAL, bronchoalveolar lavage; ILC2s, type 2 innate lymphoid cells.

plasma equivalents (EVPE; Figure 5, A and B). In contrast, TSLP did not increase ELW or EVPE, and
IL-25 caused substantially less pulmonary edema than IL-33 (Supplemental Figure 6, A and B).
Pulmonary edema resulted in a loss of static compliance (Figure 5, C and D) and reduced inspiratory
capacity indicative of a restrictive physiology (Figure 5E) that was unaffected by the IL5Tg. We did not
observe airway hyperreactivity suggestive of asthma (Supplemental Figure 6, C–F), suggesting this model
more accurately reflects the active vasculitis phase of EGPA than the asthmatic, prodromal phase.
We hypothesized that IL-33 treatment may act through ILC2s to stimulate IL-13 production, leading to
acute lung injury, vascular permeability, and resulting pulmonary edema. Consistent with this hypothesis,
we found that ILC2-deficient or IL-4 and IL-13 signaling–deficient mice had significantly reduced ELW and
EVPE after IL-33 compared with WT mice (Figure 5, F and G). Comparatively, Rag1–/– mice were not protected from increased ELW and EVPE after IL-33, suggesting that the IL-4 and IL-13 signaling that induced
vascular permeability and pulmonary edema was not dependent on T cells (Supplemental Figure 6, G and H).
Signaling through IL4Rα-mediated movement of eosinophils from the vasculature to the extravascular space.
Because IL5Tg mice on ILC2del, STAT6–/– or IL4Rα–/– backgrounds had severe hypereosinophilia but
few pulmonary intraparenchymal eosinophils and no vasculitis, we suspected that IL4Rα signaling
might promote eosinophil migration into tissue. Few lung eosinophils from saline-treated WT or IL5Tg
mice remained unlabeled after intravenous injection of anti-CD45 Ab, consistent with predominantly
intravascular localization (Figure 6A). After IL-33 treatment, however, more than 90% of the pulmonary eosinophils were unlabeled, consistent with tissue entry (Figure 6A and Supplemental Figure 7A).
JCI Insight 2021;6(11):e143366 https://doi.org/10.1172/jci.insight.143366

4

RESEARCH ARTICLE

Figure 3. ILC2s are required for development of vasculitis in hypereosinophilic mice. (A) BAL from ILC2-deficient ILC2del x IL5Tg mice (representative
of 3 mice/group). (B) Eosinophils or (C) ILC2s in BAL of IL-33–treated ILC2del x IL5Tg. ****P < 0.0001, **P < 0.01, *P < 0.05 by 1-way ANOVA with Sidak
post hoc testing. n = 3–11 mice/group. (D) H&E of lungs from representative IL-33–treated IL5Tg or ILC2del x IL5Tg mice treated with IL-33 shown in A–C
(original magnification, ×40). Scale bars: 100 μm. (E) Number of IL-13Sm13+ cells in lungs of saline-treated or IL-33–treated YYRS Smart13–knock-in mice
expressing a modified human CD4 marker from the mouse IL-13 gene locus. ILC2 defined as lin–, Thy1.2+, CD3–, Arg1YFP+, Red5+. Data are presented as
± SEM. n = 3–4 mice/group. BAL, bronchoalveolar lavage; ILC2s, type 2 innate lymphoid cells.

By comparison, only approximately 50% as many eosinophils reached the extravascular space in IL-33–
treated IL4Rα–/– or IL4Rα–/– x IL5Tg mice (Figure 6A and Supplemental Figure 7B).
Signaling via IL4Rα is known to stimulate the production of the chemokine eotaxin by multiple lung
cell types in patients with asthma (18). Consistent with these clinical observations, we found that both
IL4Rα–/– mice and IL4–/–/IL13–/– mice had significantly decreased levels of eotaxin in serum in the unperturbed state (Figure 6B). Further, eotaxin levels in both BAL and serum were strongly induced after IL-33
treatment in WT mice but not in IL4Rα–/– mice (Figure 6, C and D). Although ILC2del mice did not have
decreased serum eotaxin at baseline, we reasoned that in the setting of IL-33–induced ILC2 activation
and IL-13 production, eotaxin levels may depend on ILC2s. Indeed, eotaxin was strongly induced in
BAL and serum of WT but not in ILC2del mice after IL-33 treatment (Figure 6, E and F). In addition to
stimulating eotaxin production, IL-4 and IL-13 are also known to activate endothelial cells to upregulate
surface VCAM-1 (19, 20), which can mediate eosinophil arrest and migration (21). Indeed, IL-33–treated
IL4Rα–/– mice showed reduced vascular staining for VCAM- 1 (Supplemental Figure 7C) compared with
controls. By comparison, PECAM-1 was minimally present and unchanged, and ICAM-1 was equally
and ubiquitously expressed on epithelial cells, suggesting VCAM-1 upregulation as a mechanism through
which IL-13 acts to potentiate eosinophil tissue ingress.

Discussion
Here we suggest a role for ILC2s and IL4Rα signaling in the pathogenesis of EGPA and generate a mouse
model for study of this rare but disabling disease. We find that patients with EGPA had increased levels of
IL-25, TSLP, and sST2 in serum and had a decrease in circulating ILC2s. We present a mouse model of
eosinophilic vasculitis that recapitulates key aspects of human EGPA, in which IL-33 induces ILC2- and
IL4Rα/STAT6-dependent transformation of established hypereosinophilia into severe tissue inflammation.
Our finding of elevated IL-25, TSLP, and sST2 in patients with EGPA corroborates previous reports
(12, 13). Though we could not reliably measure IL-33 in this study, we note that the interpretation of serum
JCI Insight 2021;6(11):e143366 https://doi.org/10.1172/jci.insight.143366
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Figure 4. Deficiency of IL4Rα signaling protects from vasculitis in hypereosinophilic mice. (A) BAL from IL-33–treated IL5Tg, STAT6–/– x IL5Tg, or
IL4Rα–/– x IL5Tg. Representative of 4 or more mice/group. (B) Eosinophils in BAL of mice from A. Data are presented as ± SEM. ****P < 0.0001; **P <
0.01; *P < 0.05; ns = by 1-way ANOVA with Sidak post hoc testing. n = 2–4 mice/group. (C) ILC2s in BAL of mice from A. ***P < 0.001; *P < 0.05; ns =
by 1-way ANOVA with Sidak post hoc testing. n = 2–4 mice/group. (D) H&E staining of lungs from representative IL-33–treated IL5Tg, STAT6–/– x IL5Tg
or IL4Rα–/– x IL5Tg mice treated with IL-33, as shown in A–C (original magnification, ×10). Scale bars: 100 μm. (E) Histopathological scoring for infiltrates, (F) alveolitis, (G) giant cells, and (H) pulmonary capillaritis in ILC2del, STAT6–/–, or IL4Rα–/– with or without IL5Tg after saline or IL-33 treatment.
****P < 0.0001, ***P < 0.001, **P < 0.01; *P < 0.05 by 1-way ANOVA with Dunnett’s post hoc testing. n = 4–9 mice/group. Data are presented as
± SEM. BAL, bronchoalveolar lavage; ILC2s, type 2 innate lymphoid cells.

IL-33 levels is complicated even when technically feasible due to sequestration by serum sST2 (22) — a
system most likely devised to constrain IL-33 activity to the tissue of origin to prevent immunopathology. Further technical advances will be needed to determine whether IL-33 is elevated in affected tissues
of patients with EGPA. Whether these alarmins are cause or consequence of injury remains uncertain.
Immunopathology per se (e.g., damage attributable to excessive eosinophil degranulation in tissue) could
be the sole cause for release of these cytokines. However, the propensity of EGPA to develop late in life and
its fluctuating activity suggest that environmental triggers may be important in disease pathogenesis (23).
Thus, a reasonable hypothesis is that environmental insults provoke the initial release of cytokines such as
IL-33 at the mucosal barrier and initiate transformation to the vasculitic phase in a previously hypereosinophilic host, which then propagates further alarmin release and immunopathology.
Our finding that ILC2s were decreased in blood of patients with EGPA also replicates other studies
(24). A conflicting report compared patients with EGPA with patients with asthma, who likely have
JCI Insight 2021;6(11):e143366 https://doi.org/10.1172/jci.insight.143366
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Figure 5. IL-33 induces IL4Rα-dependent vascular leak, resulting in pulmonary edema. (A) ELW of saline-treated or IL-33–treated WT or IL5Tg mice.
n = 3–13 mice/group. (B) EVPE measured from saline-treated or IL-33–treated WT or IL5Tg mice. n = 3–13 mice/group. (C) Pressure volume curves, (D) lung
static compliance, and (E) lung inspiratory capacity in indicated mice. n = 6–8 mice/group. (F) ELW or (G) EVPE in genotypes as indicated. n = 3–9 mice/
group. Significance determined by 1-way ANOVA with Sidak post hoc testing (A, B, F, and G), or Brown-Forsyth and Welch ANOVA with Dunnett’s multiple
comparisons test (D and E). ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05. Data are presented as ± SEM. EVPE, extravascular plasma equivalents;
ELW, excess/extravascular lung water.

abnormal numbers of circulating ILC2s (13). Though a decrease in circulating ILC2s seems paradoxical,
we point out that ILC2s are largely tissue-resident. Circulating cells are capable of populating peripheral
tissue pools — which are largely regenerated by local progenitors — when turnover or demand is high
(25–27). Thus, circulating ILC2s may be depleted during active EGPA because they are recruited to
stressed or damaged tissues.
Though we and others found elevations in multiple tissue cytokines in patients, only IL-33 induced pulmonary inflammation consisting of a mixed cellular infiltrate, giant cells, pulmonary capillaritis, and eosinophilic necrosis in hypereosinophilic mice. Mouse lung ILC2s are relatively insensitive to IL-25 compared
with IL-33 (28) due to low expression of the receptor (29). Although tissue-specific receptor expression and
cytokine sensitivity in human ILC2s are not fully established (14, 30, 31), such data would inform cytokine
candidacy for induction of EGPA in patients and reveal patient-specific correlations between individual
tissue cytokine changes and specific organ involvement.
JCI Insight 2021;6(11):e143366 https://doi.org/10.1172/jci.insight.143366
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Figure 6. IL4Rα signaling facilitates eosinophil egress into tissue through recruitment and vascular activation. (A)
Extravascular (unlabeled) eosinophils (single, live, CD45+, CD11b+, CD125–, SiglecF+, SSChi cells) from saline-treated or
IL-33–treated lungs. n = 3 mice/group. (B) Eotaxin measured from serum of untreated mice as indicated. n = 3–9 mice/
group. (C) Eotaxin measured from BAL or (D) serum of saline-treated or IL-33–treated WT or IL4Rα–/– mice. n = 3–6
mice/group. (E) Eotaxin measured from BAL or (F) serum of saline-treated or IL-33–treated WT or ILC2del mice. n = 6–7
mice/group. Significance determined by 1-way ANOVA with Sidak (A, C, and D) Dunnett’s (B) or Tukey (E and F) post
hoc testing; ****P < 0.0001; ***P < 0.001; *P < 0.05. Data are presented as ± SEM. BAL, bronchoalveolar lavage; ILC2s,
type 2 innate lymphoid cells.

IL-33 has been reported to directly increase endothelial activation and vascular permeability (32, 33).
However, vascular leak was significantly improved by removal of ILC2s or IL4Rα/STAT6 signaling in
our system. Similarly, eosinophil extravasation was significantly inhibited by the loss of IL4Rα signaling,
at least in part due to reduced induction of VCAM-1 and eotaxin. By our estimate, approximately 50% of
the vascular leak and eosinophil migration after IL-33 treatment is ILC2 dependent and IL4Rα dependent,
whereas the other 50% may be attributable to direct effects of IL-33 on the endothelial or epithelial cells,
or other mechanisms. In light of their role in regulating pulmonary edema after IL-33 treatment, we find it
notable that IL-33-responsive ILC2s reside in the structures that are most critical for clearing edema fluid in
the lungs: the adventitial cuffs of bronchovascular bundles (34).
Because ILC2s produce IL-13 in the inflamed lung but minimal IL-4 (35), IL-13 is more likely drive the
phenotype, even though both cytokines signal through IL4Rα. Within this paradigm, IL-33 may activate ILC2s
JCI Insight 2021;6(11):e143366 https://doi.org/10.1172/jci.insight.143366
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to produce IL-13, which in turn stimulates eotaxin production from parenchymal cells. However, ILC2s have
also been reported to produce eotaxin (36), and therefore it is possible that ILC2s themselves may be the source
of this chemoattractant. Interestingly, we observed that although ILC2del rescued mice from alveolar hemorrhage and BAL hypereosinophilia, histopathologic findings were further improved in mice entirely deficient in
IL-4 and IL-13 signaling. This difference may be due to ILC2s that produce IL-13 but not IL-5 (therefore not
deleted in ILC2del mice) or other cell types that produce IL-13 or IL-4. Although the lack of protection from
IL-33-induced pulmonary edema in Rag1–/– mice argues against a central role for T cells in the acute vasculitic
phase, Th2 cells may be critical for the development of the asthmatic and infiltrative phases, whereas ILC2s
drive the vasculitic phase. Of note, although the ectopic expression of IL-5 in our mice precludes the ability to
investigate ILC2s as a source of IL-5, this is a point for further investigation among patients with EGPA.
Rare cases of vasculitic syndromes consistent with EGPA are reported during treatment with dupilumab, as
well as with placebo, in the context of reduced corticosteroid dose in patients with asthma (37, 38). We surmise
that some cases of EGPA may have been misdiagnosed as simple eosinophilic asthma in these trials rather than
IL4Rα blockade leading to vasculitis per se. Dupilumab is associated with increases in circulating eosinophils
(39), which seems undesirable in a disease characterized by hypereosinophilia and is worthy of caution. However, because hypereosinophilia is insufficient to cause pathology without extravascular migration and activation,
our findings raise the question of whether dual blockade of eosinophils and IL-33 or IL4Rα could be useful for
therapy in EGPA. Indeed, because dupilumab decreases eotaxin expression in patients (39), augmented peripheral eosinophilia could be a direct consequence of blocking extravascular migration and activation.
In sum, using patient samples and mouse modeling, we suggest a mechanism for the transition from
hypereosinophilia to vasculitis in EGPA. In this model, environmental insults or tissue damage led to the
release of tissue cytokines such as IL-33. This may have stimulated ILC2s to produce IL-13, which increases
pulmonary vascular permeability, eotaxin, and VCAM-1 expression, facilitating the migration of eosinophils into the extravascular space. Once in the extravascular space and in contact with activating tissue factors, these eosinophils degranulated and caused tissue damage, likely promoting further release of activating
alarmins. Our data provide a useful mouse model for further study of this rare and complex disease and
suggest that therapeutic targeting of IL-33, IL4Rα, and/or ILC2s may offer benefit in eosinophilic vasculitis.

Methods
Patients with EGPA and healthy controls. Serum and PBMCs from healthy controls were obtained at the
Etablissement Français du Sang, Saint-Antoine Hospital, Paris, France. Patients with EGPA, described
in Tables 1 and 2, fulfilled the American College of Rheumatology criteria (40) and the 2012 Chapel Hill
Consensus Conference definition (1). Patients were determined to be in the active phase of EGPA if they
had a Birmingham vasculitis activity score (BVAS; version 3.0) of 3 or greater (41), or in remission if they
had a BVAS of 0. Patients with EGPA were identified at the Vasculitis Reference Center for Vasculitis,
Cochin Hospital, Paris, France, and patients with available frozen sera were selected for cytokines measurement. Samples from age- and sex-matched healthy controls were provided to the investigators in blinded
fashion by the Etablissement Français du Sang without demographics included.
Measurement of cytokines and ILC2s from patients. PBMCs were purified from whole blood using FicollHypaque (GE Healthcare) and analyzed on a LSR Fortessa (BD Biosciences). Viability was assessed using
LIVE/DEAD viability assay (Thermo Fisher Scientific). A gating strategy for ILC2s is shown in Supplemental
Figure 1C. sST2, IL-25, TSLP, and IL-33 were quantitated using commercially available ELISAs from Tebu Bio,
Peprotech, eBioscience, and R&D Systems, respectively. IL-5 and IL-10 were quantified by Luminex (Thermo
Fisher Scientific) using the Th1/Th2/Th17 Magnetic 8-Plex Panel. Abs are listed in Supplemental Table 1.
Mice. IL5Tg (5), Arg1YFP (42), Il5Red5Cre (Red5) (10), ILC2-deleted (ILC2del) (10); STAT6–/– (43), Smart13
(35), IL4Rα–/– (44), and IL4–/–/IL13–/– (45) mice have been described. Mice were derived or backcrossed
on a C57BL/6J background for more than 10 generations, and housed under specific pathogen–free conditions with 12-hr light/day cycles and ad libitum access to food and water. Experiments were performed on
age- and sex-matched male and female mice between 8 weeks and 16 weeks of age, except for the eotaxin
experiments, in which mice were 6 months of age. IL-33 (BioLegend or R&D), TSLP (eBioscience), or
IL-25 (R&D) were administered intranasally at 0.5 μg per dose, 3 times a week for 2 weeks, and mice were
analyzed 1 day after the final dose. For intravascular labeling experiments, mice were injected intravenously
with 3 μg of anti-mouse CD45 Ab (clone 30-F11) 3 minutes prior to sacrifice. Eotaxin was measured from
serum using the Mouse CCL11/Eotaxin Quantikine ELISA Kit (R&D).
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Table 1. Characteristics of patients with EGPA examined for serum cytokines
Characteristics

Demography
Age, median [IQR]
Women, n (%)
Disease activity
BVAS, median [IQR]
Ongoing treatments
None, n (%)
Low-dose prednisone, n (%)
Immunosuppressive agents, n (%)
Laboratory features
MPO-ANCA, n (%)
Blood eosinophils, median [IQR]/mm3

Active EGPA

n = 20

Inactive EGPA
n = 35

49 [44–56]
7 (35)

52 [45–61]
15 (43)

13 [9–16]

0

7 (35)
13 (65)
6 (30)

0 (0)
35 (100)
26 (74)

8 (40)
2239 [1146–4460]

14 (40)
180 [51–770]

EGPA, eosinophilic granulomatosis with polyangiitis; ANCA, antineutrophil cytoplasm Abs; BVAS, Birmingham
vasculitis activity.

Mouse cell isolation and flow cytometry. PBMCs were isolated using Histopaque-1083 (Sigma). BAL
was obtained by instilling 1.5 mL of saline via tracheal cannulation, followed by saline perfusion.
Lung single cell suspensions were obtained by tissue digestion with 50 μg/mL Liberase (Roche) and
25 μg/mL DNAse I (Roche). Flow cytometry was performed on an LSR Fortessa and analyzed using
FlowJo (Tree Star). Dead cells were excluded by LIVE/DEAD or DAPI. A representative gating strategy for eosinophils and ILC2s is shown in Supplemental Figure 2. For IL-13 assessment by Smart13 as
in Figure 3, lung ILC2s were gated as lineage-negative, Thy1.2+, CD3–, Arg1YFP+, Red5+. Abs are listed
in Supplemental Table 1.
Microscopy. Four percent paraformaldehyde-fixed tissues were embedded in paraffin for H&E staining
or OCT (Sakura) for immunofluorescence and imaged on a Leica light microscope (H&E) or Nikon A1R
confocal microscope. Histologic appearance was evaluated in a blinded manner at a uniform anatomic
position, and a severity score of 0 (none) to 3 (severe) was assigned for alveolitis, inflammatory infiltrates,
and giant cells. Capillaritis was defined as presence (score, 1) or absence (score, 0) of hemorrhage associated with perivascular infiltration of macrophages, neutrophils, lymphocytes, and/or eosinophils. If perivascular infiltration was present without overt hemorrhage, images were scored as 0.5.

Table 2. Characteristics of patients with EGPA examined for peripheral blood ILC2s
Characteristics

Demography
Age, median [IQR]
Women, n (%)
Disease activity
BVAS, median [IQR]
Ongoing treatments
None, n (%)
Low-dose prednisone, n (%)
Immunosuppressive agents, n (%)
Laboratory features
MPO-ANCA, n (%)
Blood eosinophils, median [IQR]/mm3

Active EGPA

n=7

Inactive EGPA
n=6

54 [38–67]
4 (57)

56 [42–62]
4 (67)

15 [11–18]

0

4 (57)
3 (43)
1 (14)

1 (17)
5 (83)
2 (33)

2 (28)
1645 [980–3333]

1 (17)
140 [50–930]

EGPA, eosinophilic granulomatosis with polyangiitis; ILC2s, type 2 innate lymphoid cells; ANCA, antineutrophil
cytoplasm Abs; BVAS, Birmingham vasculitis activity.
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Lung physiology. Mice were anesthetized with ketamine and xylazine and intubated with an 18-gauge
cannula for analysis on the FlexiVent FX NPFE and Aeroneb system (SciReq). Pancuronium was used to
paralyze mice before studies of lung mechanics and methacholine challenges at the indicated doses. ELW
and EVPE were measured as previously described (46).
Statistics. Analyses were performed with GraphPad Prism 8 using 2-tailed nonparametric Mann-Whitney U
test or 1-way ANOVA with post hoc testing as appropriate. Data shown in the figures represent mean ± SEM.
Study approval. For human studies, all subjects provided written informed consent according to the Declaration of Helsinki (CPP authorization number 2011-12767). Protocols were approved by the INSERM
IRB (NEUTROVASC DR-2012-002) and the Hospital Cochin Ethics Committee. All procedures on mice
were approved by the UCSF Animal Care and Use Committee.
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